CJC-1295 (Without DAC) + Ipamorelin 5mg/5mg: The Growth Hormone Secretagogue Blend

CJC-1295 (Without DAC) + Ipamorelin 5mg/5mg: The Growth Hormone Secretagogue Blend — A Complete Research Guide

The CJC-1295 (without DAC) and Ipamorelin blend is the most studied dual-secretagogue combination in growth hormone axis research. By pairing a GHRH receptor agonist with a selective ghrelin receptor agonist, this blend produces pulsatile GH release through two distinct signalling pathways simultaneously — achieving synergistic effects that neither compound produces alone. This guide covers the mechanism, published clinical data, pulsatility science, research protocols, and how CJC-1295 without DAC compares to its DAC variant.

All products supplied by Cellovate Advanced Peptides are for laboratory research and in vitro use only. Not for human or veterinary consumption.

Table of Contents

  1. What Is the CJC-1295 + Ipamorelin Blend?
  2. The Growth Hormone Axis: Essential Background
  3. CJC-1295 (Without DAC): The GHRH Analog
  4. Ipamorelin: The Selective Ghrelin Receptor Agonist
  5. CJC-1295 With DAC vs Without DAC — A Critical Distinction
  6. The Synergy: Why This Combination Is Studied
  7. Published Clinical and Preclinical Data
  8. Research Dosing Protocols
  9. Side Effect and Safety Profile in Research
  10. Research Applications Beyond GH Stimulation
  11. Storage and Handling
  12. Sourcing for Research
  13. Frequently Asked Questions

1. What Is the CJC-1295 + Ipamorelin Blend?

The CJC-1295 (without DAC) + Ipamorelin blend is a dual-peptide research formulation combining two mechanistically distinct growth hormone secretagogues into a single vial:

  • CJC-1295 (without DAC) — 5mg — a synthetic analog of growth hormone-releasing hormone (GHRH), targeting the GHRH receptor (GHRHR) on pituitary somatotrophs
  • Ipamorelin — 5mg — a synthetic pentapeptide and highly selective agonist of the ghrelin receptor (GHS-R1a), activating a separate intracellular signalling cascade

These two compounds approach growth hormone stimulation from two different receptor entry points, activating complementary second messenger pathways that, when engaged simultaneously, produce a GH pulse significantly larger than either compound generates alone. This supra-additive effect is well-documented in peer-reviewed literature and forms the core scientific rationale for studying them as a combination rather than independently.

The blend is among the most widely referenced peptide combinations in endocrine research, performance biology, and metabolic regulation studies.

2. The Growth Hormone Axis: Essential Background

To understand why this blend works the way it does, a brief overview of the growth hormone axis is necessary.

Growth hormone (GH) is synthesised and released by somatotroph cells in the anterior pituitary gland. Its release is not continuous — it occurs in discrete pulses, primarily during sleep but also in response to exercise, fasting, and physiological stress. This pulsatile pattern is critical: sustained, non-pulsatile GH elevation is associated with receptor desensitisation and reduced downstream efficacy. Physiological GH pulses are what the body is designed to respond to.

Two endogenous hormones primarily regulate GH release from the pituitary:

GHRH (Growth Hormone-Releasing Hormone) — produced in the hypothalamus, travels to the anterior pituitary, binds to GHRHR, and stimulates GH synthesis and release via the cAMP/PKA second messenger pathway.

Ghrelin — the so-called "hunger hormone", produced primarily in the stomach, which binds to GHS-R1a receptors on pituitary somatotrophs and in the hypothalamus, activating a calcium-dependent (Gq/11) signalling cascade that amplifies GH release.

A third hormone, somatostatin, acts as the brake — it inhibits GH release and is the reason GH appears in pulses rather than continuously.

CJC-1295 (without DAC) mimics GHRH. Ipamorelin mimics ghrelin. Together, they engage both primary stimulatory pathways of the GH axis simultaneously — which is precisely what makes the combination so relevant to GH pulsatility research.

3. CJC-1295 (Without DAC): The GHRH Analog

What It Is

CJC-1295 is a synthetic analog of the first 29 amino acids of endogenous GHRH — the biologically active N-terminal fragment responsible for GHRHR binding and activation. This truncated sequence (also called Modified GRF 1-29, or Mod GRF 1-29) is engineered with four amino acid substitutions that confer resistance to dipeptidyl peptidase IV (DPP-IV), the enzyme that rapidly degrades native GHRH in circulation. Native GHRH has a plasma half-life of less than 10 minutes; CJC-1295 without DAC extends this to approximately 30 minutes.

Mechanism

Upon subcutaneous administration, CJC-1295 (without DAC) binds to GHRHR on pituitary somatotrophs and activates the Gs-coupled cAMP/PKA signalling pathway:

  1. GHRHR activation → adenylyl cyclase stimulation → increased intracellular cAMP
  2. cAMP activates protein kinase A (PKA)
  3. PKA phosphorylates CREB (cAMP response element-binding protein), driving transcription of the GH gene
  4. Increased GH synthesis → pulsatile GH secretion

This is the same pathway activated by endogenous GHRH — CJC-1295 essentially amplifies the hypothalamus's natural signal to the pituitary, producing a stronger-than-baseline GH pulse timed to the administration window.

Why "Without DAC" Matters

The half-life of approximately 30 minutes means CJC-1295 (without DAC) produces a discrete, short-duration GH pulse — the closest synthetic analogue to the physiological GHRH signal. This pulsatile pattern is what most research protocols targeting physiological GH dynamics specifically seek. The alternative — CJC-1295 with DAC — has a half-life of 6–8 days and produces sustained, non-pulsatile GH elevation. This distinction is examined in detail in section 5.

4. Ipamorelin: The Selective Ghrelin Receptor Agonist

What It Is

Ipamorelin (NNC 26-0161) is a synthetic pentapeptide developed by Novo Nordisk in the late 1990s. It is a growth hormone secretagogue receptor (GHSR-1a) agonist — meaning it binds to and activates the ghrelin receptor — but it was designed with a specific selectivity profile that distinguishes it from earlier GHRPs (growth hormone-releasing peptides).

Mechanism

Where CJC-1295 operates through the Gs/cAMP/PKA axis, Ipamorelin activates a fundamentally different intracellular cascade:

  1. GHS-R1a activation → Gq/11 protein coupling
  2. Phospholipase C (PLC) activation → IP3 and DAG production
  3. IP3 triggers intracellular calcium release from the endoplasmic reticulum
  4. Calcium influx amplifies GH granule exocytosis from somatotrophs

This calcium-dependent pathway is distinct from — and complementary to — the cAMP pathway activated by CJC-1295. The two cascades converge on the same endpoint (GH secretion) via separate molecular routes, which is the mechanistic basis for the supra-additive synergy observed when both are administered together.

Ipamorelin's Selectivity Advantage

Older GHRPs — GHRP-2, GHRP-6, Hexarelin — were effective GH secretagogues but carried significant off-target hormonal activity. GHRP-6 substantially elevates cortisol, prolactin, and ACTH alongside GH. Hexarelin can induce significant cortisol and prolactin elevation at research-relevant doses.

Ipamorelin was specifically developed to address this. Published research has consistently shown that Ipamorelin produces robust GH release with minimal effect on cortisol, prolactin, or ACTH at equivalent GH-stimulating doses. This selectivity makes it the preferred GHRP partner for research protocols where isolating GH axis effects — without confounding cortisol or prolactin variables — is experimentally important.

5. CJC-1295 With DAC vs Without DAC — A Critical Distinction

This is one of the most frequent points of confusion in growth hormone peptide research. The two forms of CJC-1295 have fundamentally different pharmacokinetics and are appropriate for different research questions.

Property CJC-1295 Without DAC CJC-1295 With DAC
Also known as Modified GRF 1-29 / Mod GRF 1-29 DAC:GRF
Half-life ~30 minutes ~6–8 days
GH release pattern Discrete, pulsatile Sustained, non-pulsatile
Receptor desensitisation risk Low Higher with chronic use
Physiological mimicry High Low
Common research pairing Ipamorelin Sometimes standalone
Albumin binding No Yes (reactive maleimide ester)

CJC-1295 without DAC is the form used in the Cellovate blend and in the majority of combination research protocols. Its short half-life produces GH pulses that more closely replicate the body's natural secretion pattern — an important variable in any research examining physiological GH dynamics, pulsatility, or downstream IGF-1 modulation.

CJC-1295 with DAC achieves prolonged GH elevation through covalent albumin binding, which dramatically extends circulating half-life. This is useful for research models requiring sustained GH elevation but introduces receptor desensitisation as a confounding variable in long-duration studies.

For most published combination research — and for the Cellovate blend — without DAC is the correct and standard form.

6. The Synergy: Why This Combination Is Studied

The core scientific argument for the CJC-1295 + Ipamorelin combination is well-supported in published literature: the two compounds activate distinct receptor pathways (GHRHR via cAMP vs GHS-R1a via calcium) that converge on GH secretion, producing a supra-additive GH pulse greater than either compound generates alone.

The mechanism of synergy is twofold:

Signal amplification at the pituitary: CJC-1295 increases GH gene transcription and primes somatotrophs for release. Ipamorelin simultaneously triggers the calcium cascade that drives GH granule exocytosis. Both signals arrive at the same cell, driving a larger secretory event than either signal alone would produce.

Somatostatin suppression: GHS-R1a agonism by Ipamorelin — and ghrelin receptor activity in the hypothalamus more broadly — has been associated with reduction in somatostatin tone during the dosing window. Since somatostatin is the primary inhibitor of GH release, reducing its activity during the CJC-1295 stimulation window further amplifies the net GH output.

The result is a research tool that can generate robust, physiologically patterned GH pulses in an experimental model — making it the dominant combination used when researchers want to study GH axis stimulation, pulsatility dynamics, or downstream IGF-1 effects in a controlled setting.

7. Published Clinical and Preclinical Data

Ionescu & Frohman (2006) — Foundational human phase I/II study of CJC-1295 (with DAC) in 21 healthy adults. Dose-escalating subcutaneous administration (30–120 mcg/kg) produced dose-dependent increases in mean GH concentrations up to 10-fold above baseline, with IGF-1 increases of 1.5–3-fold observed over the 7-day observation window. This established CJC-1295 as a potent, dose-proportional GHRH analog in humans.

Teichman et al. (2006) — Follow-up study examining multiple CJC-1295 doses in healthy adults, confirming dose-response relationship and extended duration of GH and IGF-1 elevation. Published in the Journal of Clinical Endocrinology & Metabolism.

Bowers et al. (1990) — Landmark paper on GHRP and GHRH combination synergy, demonstrating that co-administration of GHRH analog with a ghrelin-class compound produces significantly greater GH release than either alone — the foundational mechanistic basis for the CJC-1295/Ipamorelin combination.

Ipamorelin selectivity data (Novo Nordisk preclinical programme, 1990s) — Comparative studies establishing Ipamorelin's markedly lower cortisol and prolactin response relative to GHRP-2 and GHRP-6 at equi-effective GH-stimulating doses. These data defined Ipamorelin as the cleanest available GHRP from an off-target hormonal standpoint.

GHRH+GHRP combination studies — Multiple preclinical studies have confirmed the supra-additive GH release produced by dual GHRHR + GHS-R1a stimulation, with combined administration consistently producing GH pulses 2–10 times larger than either compound alone depending on dose and model.

8. Research Dosing Protocols

The following information is derived from published research protocols and is provided strictly for educational and scientific context. It does not constitute medical advice. These compounds are not approved for human use.

Published research protocols for the CJC-1295 (without DAC) + Ipamorelin combination follow consistent principles based on the pharmacokinetics of each component.

Standard research protocol (from published literature):

  • Frequency: 1–3 administrations per day
  • Timing: Typically administered before sleep (when endogenous GH pulse is largest) and/or upon waking in a fasted state
  • Dose range studied: CJC-1295 without DAC: 100–300 mcg per administration; Ipamorelin: 100–300 mcg per administration
  • Route: Subcutaneous injection
  • Duration in studies: 4–24 weeks depending on research endpoint

Timing rationale: The 30-minute half-life of CJC-1295 (without DAC) means its window of GH-stimulating activity is relatively short. Administering both peptides simultaneously — so that both receptor pathways are activated in the same window — is critical to achieving the observed synergistic GH pulse. Administration timing relative to food intake is also studied, as elevated insulin levels associated with fed states may blunt GH secretion downstream.

Protocol note: Unlike the sustained elevation produced by CJC-1295 with DAC, the without-DAC form requires more frequent administration to maintain research-relevant GH axis stimulation across experimental periods. This is considered a feature rather than a limitation in protocols where pulsatility fidelity is the research objective.

9. Side Effect and Safety Profile in Research

Ipamorelin's selectivity profile makes the CJC-1295 + Ipamorelin combination one of the better-tolerated GH secretagogue blends in published research, compared to older GHRP pairings.

Commonly observed in research subjects:

  • Mild injection site reactions (transient, dose-dependent)
  • Transient water retention in some models — a downstream effect of GH elevation
  • Mild fatigue or lethargy at initiation, typically resolving within the first week
  • Tingling or flushing sensations at time of administration in some subjects

Notably absent (relative to other GHRPs):

  • Significant cortisol elevation — Ipamorelin's key selectivity advantage
  • Significant prolactin or ACTH elevation at research doses
  • The hunger drive associated with GHRP-6 (which has strong ghrelin-like appetite stimulation beyond GH effects)

Important long-term considerations in research design: Any protocol examining extended GH axis stimulation should include IGF-1 monitoring as a downstream marker. Sustained IGF-1 elevation beyond physiological ranges is associated with cellular proliferation effects that are relevant to experimental design and subject safety in preclinical models.

10. Research Applications Beyond GH Stimulation

While the primary research application of the CJC-1295 + Ipamorelin blend is GH axis stimulation and pulsatility modelling, published research has documented downstream effects relevant to several adjacent research domains:

Metabolic research: GH is a lipolytic hormone — it promotes fat oxidation and influences glucose homeostasis. The blend is studied in metabolic models examining body composition, insulin sensitivity, and lipid metabolism in the context of GH axis activity.

Recovery and adaptation biology: GH plays a documented role in protein synthesis, nitrogen retention, and connective tissue maintenance. Research examining musculoskeletal recovery processes often includes GH axis intervention as a variable, making this blend relevant to sports science and injury repair models.

Sleep biology: Endogenous GH release is tightly coupled to slow-wave sleep. Research examining the GH/sleep relationship uses exogenous GH secretagogues to modulate this axis in controlled settings.

Ageing and longevity research: GH and IGF-1 levels decline with age — a phenomenon called somatopause. The CJC-1295 + Ipamorelin combination is studied in ageing models examining whether restoration of more youthful GH pulsatility patterns influences markers of metabolic, body composition, and functional decline.

Endocrine axis research: The blend serves as a standard research tool for studying hypothalamic-pituitary signalling, receptor cross-talk between GHRHR and GHS-R1a, and the downstream IGF-1 axis response to pulsatile vs sustained GH stimulation.

11. Storage and Handling

Lyophilised (unreconstituted):

  • Store at −20°C for long-term stability
  • Short-term refrigeration at 4°C acceptable (up to 4 weeks)
  • Protect from light and moisture

Reconstituted:

  • Reconstitute with bacteriostatic water
  • Store at 4°C; use within 28 days
  • Do not freeze after reconstitution
  • Aliquot into single-use volumes to avoid repeated freeze-thaw cycles

Both CJC-1295 and Ipamorelin are relatively stable lyophilised peptides, but as with all research-grade compounds, maintaining cold-chain conditions from supplier dispatch through laboratory use is essential for preserving biological activity.

12. Sourcing for Research

When sourcing the CJC-1295 (without DAC) + Ipamorelin blend, verify:

  • Form confirmation: Ensure the product specifies "without DAC" or "Modified GRF 1-29" — not simply "CJC-1295", which could refer to either variant
  • Independent COA: HPLC purity (≥98%) and mass spectrometry identity confirmation for both components
  • Third-party laboratory: Named, verifiable independent testing facility
  • Batch-specific documentation: Matching batch numbers across label, COA, and invoice

Cellovate Advanced Peptides supplies the CJC-1295 (without DAC) + Ipamorelin blend as a co-lyophilised, batch-tested research formulation dispatched with cold-chain packaging across Europe.

All Cellovate products are supplied strictly for laboratory research. Not for human or veterinary consumption.

13. Frequently Asked Questions

What is the difference between CJC-1295 with and without DAC? CJC-1295 without DAC (Mod GRF 1-29) has a ~30-minute half-life and produces discrete, pulsatile GH release. CJC-1295 with DAC has a ~6–8 day half-life through albumin binding, producing sustained, non-pulsatile GH elevation. The without-DAC form is used in most combination research because it more closely mirrors physiological GH secretion patterns.

Why is Ipamorelin preferred over other GHRPs? Ipamorelin is the most selective GHRP studied — it produces robust GH release with minimal off-target effects on cortisol, prolactin, or ACTH. Older GHRPs like GHRP-2 and GHRP-6 elevate cortisol significantly, which confounds research examining GH axis effects in isolation.

Why combine CJC-1295 and Ipamorelin rather than using each alone? The two compounds activate distinct receptor pathways — GHRHR (cAMP/PKA) for CJC-1295 and GHS-R1a (Gq/calcium) for Ipamorelin. Simultaneous activation of both pathways produces a supra-additive GH pulse larger than either compound achieves alone. Published research consistently demonstrates this synergistic relationship.

How does this blend relate to IGF-1? GH secreted in response to the blend reaches the liver, where it stimulates IGF-1 (Insulin-like Growth Factor 1) synthesis. IGF-1 mediates many of GH's downstream effects on protein synthesis, cell growth, and metabolic regulation. Researchers studying IGF-1 axis dynamics often use GH secretagogue blends as the experimental stimulus.

Is this combination approved for human use? No. Neither CJC-1295 (without DAC) nor Ipamorelin is approved by the FDA, EMA, or MHRA as a therapeutic drug. Both are investigational research compounds available for laboratory use only.

What makes this different from injectable GH (HGH)? Exogenous recombinant human growth hormone (rhGH) directly replaces GH — it bypasses the natural axis entirely. CJC-1295 + Ipamorelin stimulates the pituitary to produce and release its own GH, preserving the pulsatile release pattern and the downstream feedback mechanisms. This distinction is central to research comparing endogenous GH stimulation models with direct GH replacement.

Final Note

The CJC-1295 (without DAC) + Ipamorelin blend occupies a unique position in growth hormone research: it is the most physiologically faithful synthetic model for studying pulsatile GH axis stimulation. By engaging GHRHR and GHS-R1a simultaneously through distinct intracellular cascades, it produces GH pulses that are larger than either compound alone, more closely timed to endogenous secretion patterns, and — thanks to Ipamorelin's selectivity — relatively clean from an off-target hormonal standpoint.

For researchers investigating GH pulsatility, hypothalamic-pituitary signalling, IGF-1 axis dynamics, or downstream metabolic and recovery effects of GH stimulation, this combination is the standard dual-secretagogue research tool.

Cellovate Advanced Peptides supplies the CJC-1295 (without DAC) + Ipamorelin 5mg/5mg blend as a co-lyophilised, batch-tested research formulation with full cold-chain dispatch across Europe.

This article is for educational and research purposes only. All Cellovate Advanced Peptides products are supplied strictly for laboratory research and in vitro use. Not for human or veterinary consumption. Nothing in this article constitutes medical advice. Sources: Ionescu & Frohman, J Clin Endocrinol Metab 2006; Teichman SL et al., J Clin Endocrinol Metab 2006; Bowers CY et al., Endocrinology 1990; Kojima M et al., Nature 1999; Peptide Sciences research documentation.